HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

upifitimab rilsodotin

Discovery priority: MEDIUM · PROBABLE STRANDED

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: UNKNOWN

MODEL INFERENCE · MEDIUM confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2023-07 · program:reported development discontinuation

July 2023; month precision only

SOURCE TEXT · Exact source

In July 2023, we decided to discontinue the development of upifitimab rilsodotin (XMT-1536), or UpRi, and began to wind-down our UpRi-related development activities, including several clinical trials of UpRi, and our regulatory and commercial readiness efforts.

Present scoped control, intervening transfers, obligations and availability unverified

Interpretation: inadequate public evidence · MACHINE_REVIEW · MEDIUM

Provenance and retrieval scope
{
  "hash": "461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab",
  "metadata": {
    "complete": true,
    "content_hash": "461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab",
    "failed": false,
    "last_checked": 1790027032.7475095,
    "last_success": 1790027032.7475095,
    "live_verified": true,
    "scope": "Historical filing text; present ownership/availability not confirmed"
  },
  "raw_path": "research/obz7_sources/461124a4dbc9080b07af422c9915e054bde2581120cd231f9df220e69212e2ab.html",
  "type": "sec",
  "url": "https://www.sec.gov/Archives/edgar/data/1442836/000162828025040017/mrsn-20250630.htm"
}

2023-07 · program:reported development discontinuation

July 2023; month precision only

SOURCE TEXT · Exact source

In July 2023, we decided to discontinue the development of upifitimab rilsodotin (XMT-1536), or UpRi, and began to wind-down our UpRi-related development activities, including several clinical trials of UpRi, and our regulatory and commercial readiness efforts.

Present scoped control, intervening transfers, obligations and availability unverified

Interpretation: inadequate public evidence · MACHINE_REVIEW · MEDIUM

Provenance and retrieval scope
{
  "hash": "814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09",
  "metadata": {
    "complete": true,
    "content_hash": "814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09",
    "failed": false,
    "last_checked": 1790027033.7340825,
    "last_success": 1790027033.7340825,
    "live_verified": true,
    "scope": "Historical filing text; present ownership/availability not confirmed"
  },
  "raw_path": "research/obz7_sources/814c5248219607362ac309a1fdfb254f6b0d413a86707d1dfbaf7c818007ff09.html",
  "type": "sec",
  "url": "https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

clinicaltrials · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · STALE · Historical filing text; present ownership/availability not confirmed · checked 2026-09-21T21:43:52.747509+00:00

sec · STALE · Historical filing text; present ownership/availability not confirmed · checked 2026-09-21T21:43:53.734082+00:00

Registry observations (0)
Back to discovery